P. Kent Hawryluk, Director at Gemphire Therapeutics Inc. (GEMP), bought 50,000 shares at $9.47 ($474K) on 2017-03-10, disclosed to the SEC on 2017-03-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.47 | 25,000 | $237K | 50.0% |
| 2 | $9.47 | 25,000 | $237K | 50.0% |
| Total | $9.47 avg | 50,000 | $474K | 100% |
| Filing → |
| MBX | BUY | 2025-10-21 | $273K | — | Filing → |
| MBX | BUY | 2025-02-05 | $535K | — | Filing → |
| GEMP | BUY | 2016-08-12 | $250K | — | Filing → |